English

iTeos Therapeutics, Inc.

EDGAR

ITOS Quarterly report (10-Q) · filed 2025-08-06

Annual consolidated revenue for 2024: about USD 35M, using the latest reported figures. The previous period, 2023, was about USD 12.6M.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

0 USD

2025 Q2 · USD

Exact inputs and evidence

Revenue: 0 USD Source

Operating cash flow

-42.4 million USD

2025 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -76210000 USD Source
Operating Cash Flow: -33764000 USD Source

Free cash flow

-42.7 million USD

2025 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -76210000 USD Source
Operating Cash Flow: -33764000 USD Source
Capital Expenditure: 384000 USD Source
Capital Expenditure: 101000 USD Source

Cash and cash equivalents: 208 million USD 2025-06-30 Source
Exact value

207820000 USD
Long-term debt including current maturities: Not available
Shares outstanding: 38.3 million shares 2025-06-30 Source
Exact value

38271682 shares

Reported share-count change

4.80% · 1.75 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

36519945 shares · 2024-06-30· Source
38271682 shares · 2025-06-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Net income

-202 million USD

2024-07-01 – 2025-06-30

Exact inputs and evidence

Net income: -45400000 USD · 2024-07-01 – 2024-09-30 Source
Net income: -134400000 USD · 2024-01-01 – 2024-12-31 Source
Net income: -90700000 USD · 2024-01-01 – 2024-09-30 Source
Net income: -34613000 USD · 2025-01-01 – 2025-03-31 Source
Net income: -78729000 USD · 2025-04-01 – 2025-06-30 Source

Operating cash flow

-108 million USD

2024-07-01 – 2025-06-30

Exact inputs and evidence

Operating cash flow: -103678000 USD · 2024-01-01 – 2024-09-30 Source
Operating cash flow: -66327000 USD · 2024-01-01 – 2024-06-30 Source
Operating cash flow: -98181000 USD · 2024-01-01 – 2024-12-31 Source
Operating cash flow: -103678000 USD · 2024-01-01 – 2024-09-30 Source
Operating cash flow: -33764000 USD · 2025-01-01 – 2025-03-31 Source
Operating cash flow: -76210000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -33764000 USD · 2025-01-01 – 2025-03-31 Source

Capital expenditure

630 thousand USD

2024-07-01 – 2025-06-30

Exact inputs and evidence

Capital expenditure: 1481000 USD · 2024-01-01 – 2024-09-30 Source
Capital expenditure: 1387000 USD · 2024-01-01 – 2024-06-30 Source
Capital expenditure: 1633000 USD · 2024-01-01 – 2024-12-31 Source
Capital expenditure: 1481000 USD · 2024-01-01 – 2024-09-30 Source
Capital expenditure: 101000 USD · 2025-01-01 – 2025-03-31 Source
Capital expenditure: 384000 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 101000 USD · 2025-01-01 – 2025-03-31 Source

Free cash flow

-109 million USD

2024-07-01 – 2025-06-30

Exact inputs and evidence

Operating cash flow: -103678000 USD · 2024-01-01 – 2024-09-30 Source
Operating cash flow: -66327000 USD · 2024-01-01 – 2024-06-30 Source
Operating cash flow: -98181000 USD · 2024-01-01 – 2024-12-31 Source
Operating cash flow: -103678000 USD · 2024-01-01 – 2024-09-30 Source
Operating cash flow: -33764000 USD · 2025-01-01 – 2025-03-31 Source
Operating cash flow: -76210000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -33764000 USD · 2025-01-01 – 2025-03-31 Source
Capital expenditure: 1481000 USD · 2024-01-01 – 2024-09-30 Source
Capital expenditure: 1387000 USD · 2024-01-01 – 2024-06-30 Source
Capital expenditure: 1633000 USD · 2024-01-01 – 2024-12-31 Source
Capital expenditure: 1481000 USD · 2024-01-01 – 2024-09-30 Source
Capital expenditure: 101000 USD · 2025-01-01 – 2025-03-31 Source
Capital expenditure: 384000 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 101000 USD · 2025-01-01 – 2025-03-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2025-08-06.

Financial data available through: 2024-12-31.

Coverage by financial measure

Revenue: 4 of 11 periods available· newest 2024-12-31
Operating income: 6 of 11 periods available· newest 2024-12-31
Net income: 6 of 11 periods available· newest 2024-12-31
Operating cash flow: 6 of 11 periods available· newest 2024-12-31
Capital expenditure: 6 of 11 periods available· newest 2024-12-31
Total assets: 4 of 11 periods available· newest 2024-12-31
Total liabilities: 4 of 11 periods available· newest 2024-12-31
Current assets: 4 of 11 periods available· newest 2024-12-31
Current liabilities: 4 of 11 periods available· newest 2024-12-31
Cash and cash equivalents: 4 of 11 periods available· newest 2024-12-31
long term debt: No compatible figures in this window
Shares outstanding: 4 of 11 periods available· newest 2024-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+177.9%

Prior period

USD 12.6 million

2023-01-01 – 2023-12-31
Current period

USD 35 million

2024-01-01 – 2024-12-31

Exact inputs and evidence

35000000 − 12595000 = 22405000 USD

12595000 USD · 2023-01-01 – 2023-12-31
Inspect prior input Prior source
35000000 USD · 2024-01-01 – 2024-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · iTeos Therapeutics, Inc. · 2024-12-31 iTeos Therapeutics, Inc. (edgar:1808865) Year-over-year change in Revenue: 22405000 USD Concept: fundies:Revenue Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T11:14:41Z Snapshot: 3bc84d46dc924d83216b56ecc732a1ddeff5737085046a07b53297302179d7bf Dimensions: Consolidated View: https://fundies.io/companies/edgar/1808865?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 35000000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1808865/000095017025033066/itos-20241231.htm#3157673 Filing: 000095017025033066 Input fundies:Revenue: 12595000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1808865/000095017025033066/itos-20241231.htm#3159361 Filing: 000095017025033066
The citation records this snapshot. The page link may show a newer release later.
Net income
−USD 21.8 million

Prior period

−USD 112.6 million

2023-01-01 – 2023-12-31
Current period

−USD 134.4 million

2024-01-01 – 2024-12-31

Exact inputs and evidence

-134400000 − -112600000 = -21800000 USD

-112600000 USD · 2023-01-01 – 2023-12-31
Inspect prior input Prior source
-134400000 USD · 2024-01-01 – 2024-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · iTeos Therapeutics, Inc. · 2024-12-31 iTeos Therapeutics, Inc. (edgar:1808865) Year-over-year change in Net income: -21800000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T11:14:41Z Snapshot: 3bc84d46dc924d83216b56ecc732a1ddeff5737085046a07b53297302179d7bf Dimensions: Consolidated View: https://fundies.io/companies/edgar/1808865?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -134400000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1808865/000095017025033066/itos-20241231.htm#2129881 Filing: 000095017025033066 Input fundies:NetIncome: -112600000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1808865/000095017025033066/itos-20241231.htm#2128363 Filing: 000095017025033066
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+USD 5.58 million

Prior period

−USD 103.76 million

2023-01-01 – 2023-12-31
Current period

−USD 98.18 million

2024-01-01 – 2024-12-31

Exact inputs and evidence

-98181000 − -103756000 = 5575000 USD

-103756000 USD · 2023-01-01 – 2023-12-31
Inspect prior input Prior source
-98181000 USD · 2024-01-01 – 2024-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · iTeos Therapeutics, Inc. · 2024-12-31 iTeos Therapeutics, Inc. (edgar:1808865) Year-over-year change in Operating cash flow: 5575000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T11:14:41Z Snapshot: 3bc84d46dc924d83216b56ecc732a1ddeff5737085046a07b53297302179d7bf Dimensions: Consolidated View: https://fundies.io/companies/edgar/1808865?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -98181000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1808865/000095017025033066/itos-20241231.htm#2019194 Filing: 000095017025033066 Input fundies:OperatingCashFlow: -103756000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1808865/000095017025033066/itos-20241231.htm#2020915 Filing: 000095017025033066
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-44.9%

Prior period

USD 2.97 million

2023-01-01 – 2023-12-31
Current period

USD 1.63 million

2024-01-01 – 2024-12-31

Exact inputs and evidence

1633000 − 2966000 = -1333000 USD

2966000 USD · 2023-01-01 – 2023-12-31
Inspect prior input Prior source
1633000 USD · 2024-01-01 – 2024-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · iTeos Therapeutics, Inc. · 2024-12-31 iTeos Therapeutics, Inc. (edgar:1808865) Year-over-year change in Capital expenditure: -1333000 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T11:14:41Z Snapshot: 3bc84d46dc924d83216b56ecc732a1ddeff5737085046a07b53297302179d7bf Dimensions: Consolidated View: https://fundies.io/companies/edgar/1808865?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 1633000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1808865/000095017025033066/itos-20241231.htm#2033069 Filing: 000095017025033066 Input fundies:CapitalExpenditure: 2966000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1808865/000095017025033066/itos-20241231.htm#2034780 Filing: 000095017025033066
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2024 2024-01-01 – 2024-12-31

Revenue USD 35 million 100% of revenue
Operating costs Derived USD 194.53 million 556% of revenue
Operating income −USD 159.53 million −456% of revenue
Tax, interest and other Derived −USD 25.13 million −72% of revenue
Net income −USD 134.4 million −384% of revenue

Cash

Operating cash flow −USD 98.18 million −281% of revenue
Capital expenditure USD 1.63 million 4.7% of revenue
Free cash flow Derived −USD 99.81 million −285% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2021 62%29%
2022 36%11%53%
2023 Operating loss: operating costs were 1,300% of revenue.
2024 Operating loss: operating costs were 556% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2021 2021-01-01 – 2021-12-31	344775000	99874000 Derived	244901000	30401000 Derived	214500000	511959000 Derived	Source 2021-01-01 – 2021-12-31: 344775000 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: 244901000 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: 214500000 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: 513140000 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 1181000 USD Inspect Capital Expenditure Open source
2022 2022-01-01 – 2022-12-31	267630000	141306000 Derived	126324000	29624000 Derived	96700000	-112131000 Derived	Source 2022-01-01 – 2022-12-31: 267630000 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: 126324000 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: 96700000 USD Inspect Net Income Open source 2022-01-01 – 2022-12-31: -111193000 USD Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 938000 USD Inspect Capital Expenditure Open source
2023 2023-01-01 – 2023-12-31	12595000	163696000 Derived	-151101000	-38501000 Derived	-112600000	-106722000 Derived	Source 2023-01-01 – 2023-12-31: 12595000 USD Inspect Revenue Open source 2023-01-01 – 2023-12-31: -151101000 USD Inspect Operating Income Open source 2023-01-01 – 2023-12-31: -112600000 USD Inspect Net Income Open source 2023-01-01 – 2023-12-31: -103756000 USD Inspect Operating Cash Flow Open source 2023-01-01 – 2023-12-31: 2966000 USD Inspect Capital Expenditure Open source
2024 2024-01-01 – 2024-12-31	35000000	194528000 Derived	-159528000	-25128000 Derived	-134400000	-99814000 Derived	Source 2024-01-01 – 2024-12-31: 35000000 USD Inspect Revenue Open source 2024-01-01 – 2024-12-31: -159528000 USD Inspect Operating Income Open source 2024-01-01 – 2024-12-31: -134400000 USD Inspect Net Income Open source 2024-01-01 – 2024-12-31: -98181000 USD Inspect Operating Cash Flow Open source 2024-01-01 – 2024-12-31: 1633000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 35M 2024

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20212021-12-31	Revenue	344775000	Revenue: 344775000 Open source
20222022-12-31	Revenue	267630000	Revenue: 267630000 Open source
20232023-12-31	Revenue	12595000	Revenue: 12595000 Open source
20242024-12-31	Revenue	35000000	Revenue: 35000000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

177.9% 2024

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20212021-12-31	Year over year	No prior comparable period	Revenue: 344775000 Open source
20222022-12-31	Year over year	-22.4%	Revenue: 267630000 Open source Revenue: 344775000 Open source
20232023-12-31	Year over year	-95.3%	Revenue: 12595000 Open source Revenue: 267630000 Open source
20242024-12-31	Year over year	177.9%	Revenue: 35000000 Open source Revenue: 12595000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -455.8% 2024

Net margin -384% 2024

Free cash flow margin -285.2% 2024

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20212021-12-31	Operating margin	71%	Operating Income: 244901000 Open source Revenue: 344775000 Open source
20222022-12-31	Operating margin	47.2%	Operating Income: 126324000 Open source Revenue: 267630000 Open source
20232023-12-31	Operating margin	-1,199.7%	Operating Income: -151101000 Open source Revenue: 12595000 Open source
20242024-12-31	Operating margin	-455.8%	Operating Income: -159528000 Open source Revenue: 35000000 Open source
20212021-12-31	Net margin	62.2%	Net Income: 214500000 Open source Revenue: 344775000 Open source
20222022-12-31	Net margin	36.1%	Net Income: 96700000 Open source Revenue: 267630000 Open source
20232023-12-31	Net margin	-894%	Net Income: -112600000 Open source Revenue: 12595000 Open source
20242024-12-31	Net margin	-384%	Net Income: -134400000 Open source Revenue: 35000000 Open source
20212021-12-31	Free cash flow margin	148.5%	Revenue: 344775000 Open source Operating Cash Flow: 513140000 Open source Capital Expenditure: 1181000 Open source
20222022-12-31	Free cash flow margin	-41.9%	Revenue: 267630000 Open source Operating Cash Flow: -111193000 Open source Capital Expenditure: 938000 Open source
20232023-12-31	Free cash flow margin	-847.3%	Revenue: 12595000 Open source Operating Cash Flow: -103756000 Open source Capital Expenditure: 2966000 Open source
20242024-12-31	Free cash flow margin	-285.2%	Revenue: 35000000 Open source Operating Cash Flow: -98181000 Open source Capital Expenditure: 1633000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -98.2M 2024

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20212021-12-31	Operating cash flow	513140000	Operating Cash Flow: 513140000 Open source
20222022-12-31	Operating cash flow	-111193000	Operating Cash Flow: -111193000 Open source
20232023-12-31	Operating cash flow	-103756000	Operating Cash Flow: -103756000 Open source
20242024-12-31	Operating cash flow	-98181000	Operating Cash Flow: -98181000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -99.8M 2024

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20212021-12-31	Free cash flow	511959000	Operating Cash Flow: 513140000 Open source Capital Expenditure: 1181000 Open source
20222022-12-31	Free cash flow	-112131000	Operating Cash Flow: -111193000 Open source Capital Expenditure: 938000 Open source
20232023-12-31	Free cash flow	-106722000	Operating Cash Flow: -103756000 Open source Capital Expenditure: 2966000 Open source
20242024-12-31	Free cash flow	-99814000	Operating Cash Flow: -98181000 Open source Capital Expenditure: 1633000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

14.1% 2024

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20212021-12-31	Liabilities / assets	37.5%	Total Liabilities: 331892000 Open source Total Assets: 884712000 Open source
20222022-12-31	Liabilities / assets	12.1%	Total Liabilities: 91659000 Open source Total Assets: 754991000 Open source
20232023-12-31	Liabilities / assets	13.8%	Total Liabilities: 92360000 Open source Total Assets: 667588000 Open source
20242024-12-31	Liabilities / assets	14.1%	Total Liabilities: 96682000 Open source Total Assets: 686976000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

12.62× 2024

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20212021-12-31	Current assets / current liabilities	2.88×	Current Assets: 874713000 Open source Current Liabilities: 304124000 Open source
20222022-12-31	Current assets / current liabilities	14.96×	Current Assets: 628298000 Open source Current Liabilities: 42000000 Open source
20232023-12-31	Current assets / current liabilities	13.76×	Current Assets: 550652000 Open source Current Liabilities: 40014000 Open source
20242024-12-31	Current assets / current liabilities	12.62×	Current Assets: 509539000 Open source Current Liabilities: 40360000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2019 2019-01-01 – 2019-12-31	−USD 22.45 million Exact value Exact value: -22454000 USD 2019-01-01 – 2019-12-31: -22454000 USD Inspect Net Income Open source Share or cite Citation for Net Income · iTeos Therapeutics, Inc. · 2019-12-31 iTeos Therapeutics, Inc. (edgar:1808865) Net Income: -22454000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T11:14:41Z Snapshot: 3bc84d46dc924d83216b56ecc732a1ddeff5737085046a07b53297302179d7bf Dimensions: Consolidated View: https://fundies.io/companies/edgar/1808865/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -22454000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1808865/000156459021015146/itos-20201231.xml#127476 Filing: 000156459021015146 The citation records this snapshot. The page link may show a newer release later.	−USD 23.15 million Exact value Exact value: -23145000 USD 2019-01-01 – 2019-12-31: -23145000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · iTeos Therapeutics, Inc. · 2019-12-31 iTeos Therapeutics, Inc. (edgar:1808865) Operating Cash Flow: -23145000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T11:14:41Z Snapshot: 3bc84d46dc924d83216b56ecc732a1ddeff5737085046a07b53297302179d7bf Dimensions: Consolidated View: https://fundies.io/companies/edgar/1808865/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -23145000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1808865/000156459021015146/itos-20201231.xml#155186 Filing: 000156459021015146 The citation records this snapshot. The page link may show a newer release later.	USD 721,000 Exact value Exact value: 721000 USD 2019-01-01 – 2019-12-31: 721000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · iTeos Therapeutics, Inc. · 2019-12-31 iTeos Therapeutics, Inc. (edgar:1808865) Capital Expenditure: 721000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T11:14:41Z Snapshot: 3bc84d46dc924d83216b56ecc732a1ddeff5737085046a07b53297302179d7bf Dimensions: Consolidated View: https://fundies.io/companies/edgar/1808865/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 721000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1808865/000156459021015146/itos-20201231.xml#155607 Filing: 000156459021015146 The citation records this snapshot. The page link may show a newer release later.	−USD 23.87 million Calculation and evidence -23145000 − 721000 USD Exact free cash flow: -23866000 USD 2019-01-01 – 2019-12-31: -23145000 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 721000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · iTeos Therapeutics, Inc. · 2019-12-31 iTeos Therapeutics, Inc. (edgar:1808865) Free cash flow: -23866000 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T11:14:41Z Snapshot: 3bc84d46dc924d83216b56ecc732a1ddeff5737085046a07b53297302179d7bf Dimensions: Consolidated View: https://fundies.io/companies/edgar/1808865?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -23145000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1808865/000156459021015146/itos-20201231.xml#155186 Filing: 000156459021015146 Input fundies:CapitalExpenditure: 721000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1808865/000156459021015146/itos-20201231.xml#155607 Filing: 000156459021015146 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	−USD 38.03 million Exact value Exact value: -38033000 USD 2020-01-01 – 2020-12-31: -38033000 USD Inspect Net Income Open source Share or cite Citation for Net Income · iTeos Therapeutics, Inc. · 2020-12-31 iTeos Therapeutics, Inc. (edgar:1808865) Net Income: -38033000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T11:14:41Z Snapshot: 3bc84d46dc924d83216b56ecc732a1ddeff5737085046a07b53297302179d7bf Dimensions: Consolidated View: https://fundies.io/companies/edgar/1808865/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -38033000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1808865/000095017022004409/itos-20211231.htm#1951056 Filing: 000095017022004409 The citation records this snapshot. The page link may show a newer release later.	−USD 25.18 million Exact value Exact value: -25176000 USD 2020-01-01 – 2020-12-31: -25176000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · iTeos Therapeutics, Inc. · 2020-12-31 iTeos Therapeutics, Inc. (edgar:1808865) Operating Cash Flow: -25176000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T11:14:41Z Snapshot: 3bc84d46dc924d83216b56ecc732a1ddeff5737085046a07b53297302179d7bf Dimensions: Consolidated View: https://fundies.io/companies/edgar/1808865/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -25176000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1808865/000095017022004409/itos-20211231.htm#2131192 Filing: 000095017022004409 The citation records this snapshot. The page link may show a newer release later.	USD 356,000 Exact value Exact value: 356000 USD 2020-01-01 – 2020-12-31: 356000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · iTeos Therapeutics, Inc. · 2020-12-31 iTeos Therapeutics, Inc. (edgar:1808865) Capital Expenditure: 356000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T11:14:41Z Snapshot: 3bc84d46dc924d83216b56ecc732a1ddeff5737085046a07b53297302179d7bf Dimensions: Consolidated View: https://fundies.io/companies/edgar/1808865/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 356000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1808865/000095017022004409/itos-20211231.htm#2138104 Filing: 000095017022004409 The citation records this snapshot. The page link may show a newer release later.	−USD 25.53 million Calculation and evidence -25176000 − 356000 USD Exact free cash flow: -25532000 USD 2020-01-01 – 2020-12-31: -25176000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 356000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · iTeos Therapeutics, Inc. · 2020-12-31 iTeos Therapeutics, Inc. (edgar:1808865) Free cash flow: -25532000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T11:14:41Z Snapshot: 3bc84d46dc924d83216b56ecc732a1ddeff5737085046a07b53297302179d7bf Dimensions: Consolidated View: https://fundies.io/companies/edgar/1808865?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -25176000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1808865/000095017022004409/itos-20211231.htm#2131192 Filing: 000095017022004409 Input fundies:CapitalExpenditure: 356000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1808865/000095017022004409/itos-20211231.htm#2138104 Filing: 000095017022004409 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	USD 214.5 million Exact value Exact value: 214500000 USD 2021-01-01 – 2021-12-31: 214500000 USD Inspect Net Income Open source Share or cite Citation for Net Income · iTeos Therapeutics, Inc. · 2021-12-31 iTeos Therapeutics, Inc. (edgar:1808865) Net Income: 214500000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T11:14:41Z Snapshot: 3bc84d46dc924d83216b56ecc732a1ddeff5737085046a07b53297302179d7bf Dimensions: Consolidated View: https://fundies.io/companies/edgar/1808865/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: 214500000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1808865/000095017024026866/itos-20231231.htm#1979835 Filing: 000095017024026866 The citation records this snapshot. The page link may show a newer release later.	USD 513.14 million Exact value Exact value: 513140000 USD 2021-01-01 – 2021-12-31: 513140000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · iTeos Therapeutics, Inc. · 2021-12-31 iTeos Therapeutics, Inc. (edgar:1808865) Operating Cash Flow: 513140000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T11:14:41Z Snapshot: 3bc84d46dc924d83216b56ecc732a1ddeff5737085046a07b53297302179d7bf Dimensions: Consolidated View: https://fundies.io/companies/edgar/1808865/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 513140000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1808865/000095017024026866/itos-20231231.htm#1881325 Filing: 000095017024026866 The citation records this snapshot. The page link may show a newer release later.	USD 1.18 million Exact value Exact value: 1181000 USD 2021-01-01 – 2021-12-31: 1181000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · iTeos Therapeutics, Inc. · 2021-12-31 iTeos Therapeutics, Inc. (edgar:1808865) Capital Expenditure: 1181000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T11:14:41Z Snapshot: 3bc84d46dc924d83216b56ecc732a1ddeff5737085046a07b53297302179d7bf Dimensions: Consolidated View: https://fundies.io/companies/edgar/1808865/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1181000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1808865/000095017024026866/itos-20231231.htm#1897167 Filing: 000095017024026866 The citation records this snapshot. The page link may show a newer release later.	USD 511.96 million Calculation and evidence 513140000 − 1181000 USD Exact free cash flow: 511959000 USD 2021-01-01 – 2021-12-31: 513140000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 1181000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · iTeos Therapeutics, Inc. · 2021-12-31 iTeos Therapeutics, Inc. (edgar:1808865) Free cash flow: 511959000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T11:14:41Z Snapshot: 3bc84d46dc924d83216b56ecc732a1ddeff5737085046a07b53297302179d7bf Dimensions: Consolidated View: https://fundies.io/companies/edgar/1808865?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 513140000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1808865/000095017024026866/itos-20231231.htm#1881325 Filing: 000095017024026866 Input fundies:CapitalExpenditure: 1181000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1808865/000095017024026866/itos-20231231.htm#1897167 Filing: 000095017024026866 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	USD 96.7 million Exact value Exact value: 96700000 USD 2022-01-01 – 2022-12-31: 96700000 USD Inspect Net Income Open source Share or cite Citation for Net Income · iTeos Therapeutics, Inc. · 2022-12-31 iTeos Therapeutics, Inc. (edgar:1808865) Net Income: 96700000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T11:14:41Z Snapshot: 3bc84d46dc924d83216b56ecc732a1ddeff5737085046a07b53297302179d7bf Dimensions: Consolidated View: https://fundies.io/companies/edgar/1808865/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: 96700000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1808865/000095017024026866/itos-20231231.htm#1980370 Filing: 000095017024026866 The citation records this snapshot. The page link may show a newer release later.	−USD 111.19 million Exact value Exact value: -111193000 USD 2022-01-01 – 2022-12-31: -111193000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · iTeos Therapeutics, Inc. · 2022-12-31 iTeos Therapeutics, Inc. (edgar:1808865) Operating Cash Flow: -111193000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T11:14:41Z Snapshot: 3bc84d46dc924d83216b56ecc732a1ddeff5737085046a07b53297302179d7bf Dimensions: Consolidated View: https://fundies.io/companies/edgar/1808865/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -111193000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1808865/000095017024026866/itos-20231231.htm#1880027 Filing: 000095017024026866 The citation records this snapshot. The page link may show a newer release later.	USD 938,000 Exact value Exact value: 938000 USD 2022-01-01 – 2022-12-31: 938000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · iTeos Therapeutics, Inc. · 2022-12-31 iTeos Therapeutics, Inc. (edgar:1808865) Capital Expenditure: 938000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T11:14:41Z Snapshot: 3bc84d46dc924d83216b56ecc732a1ddeff5737085046a07b53297302179d7bf Dimensions: Consolidated View: https://fundies.io/companies/edgar/1808865/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 938000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1808865/000095017024026866/itos-20231231.htm#1895784 Filing: 000095017024026866 The citation records this snapshot. The page link may show a newer release later.	−USD 112.13 million Calculation and evidence -111193000 − 938000 USD Exact free cash flow: -112131000 USD 2022-01-01 – 2022-12-31: -111193000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 938000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · iTeos Therapeutics, Inc. · 2022-12-31 iTeos Therapeutics, Inc. (edgar:1808865) Free cash flow: -112131000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T11:14:41Z Snapshot: 3bc84d46dc924d83216b56ecc732a1ddeff5737085046a07b53297302179d7bf Dimensions: Consolidated View: https://fundies.io/companies/edgar/1808865?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -111193000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1808865/000095017024026866/itos-20231231.htm#1880027 Filing: 000095017024026866 Input fundies:CapitalExpenditure: 938000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1808865/000095017024026866/itos-20231231.htm#1895784 Filing: 000095017024026866 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−USD 112.6 million Exact value Exact value: -112600000 USD 2023-01-01 – 2023-12-31: -112600000 USD Inspect Net Income Open source Share or cite Citation for Net Income · iTeos Therapeutics, Inc. · 2023-12-31 iTeos Therapeutics, Inc. (edgar:1808865) Net Income: -112600000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T11:14:41Z Snapshot: 3bc84d46dc924d83216b56ecc732a1ddeff5737085046a07b53297302179d7bf Dimensions: Consolidated View: https://fundies.io/companies/edgar/1808865/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -112600000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1808865/000095017025033066/itos-20241231.htm#2128363 Filing: 000095017025033066 The citation records this snapshot. The page link may show a newer release later.	−USD 103.76 million Exact value Exact value: -103756000 USD 2023-01-01 – 2023-12-31: -103756000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · iTeos Therapeutics, Inc. · 2023-12-31 iTeos Therapeutics, Inc. (edgar:1808865) Operating Cash Flow: -103756000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T11:14:41Z Snapshot: 3bc84d46dc924d83216b56ecc732a1ddeff5737085046a07b53297302179d7bf Dimensions: Consolidated View: https://fundies.io/companies/edgar/1808865/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -103756000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1808865/000095017025033066/itos-20241231.htm#2020915 Filing: 000095017025033066 The citation records this snapshot. The page link may show a newer release later.	USD 2.97 million Exact value Exact value: 2966000 USD 2023-01-01 – 2023-12-31: 2966000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · iTeos Therapeutics, Inc. · 2023-12-31 iTeos Therapeutics, Inc. (edgar:1808865) Capital Expenditure: 2966000 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T11:14:41Z Snapshot: 3bc84d46dc924d83216b56ecc732a1ddeff5737085046a07b53297302179d7bf Dimensions: Consolidated View: https://fundies.io/companies/edgar/1808865/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 2966000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1808865/000095017025033066/itos-20241231.htm#2034780 Filing: 000095017025033066 The citation records this snapshot. The page link may show a newer release later.	−USD 106.72 million Calculation and evidence -103756000 − 2966000 USD Exact free cash flow: -106722000 USD 2023-01-01 – 2023-12-31: -103756000 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 2966000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · iTeos Therapeutics, Inc. · 2023-12-31 iTeos Therapeutics, Inc. (edgar:1808865) Free cash flow: -106722000 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T11:14:41Z Snapshot: 3bc84d46dc924d83216b56ecc732a1ddeff5737085046a07b53297302179d7bf Dimensions: Consolidated View: https://fundies.io/companies/edgar/1808865?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -103756000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1808865/000095017025033066/itos-20241231.htm#2020915 Filing: 000095017025033066 Input fundies:CapitalExpenditure: 2966000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1808865/000095017025033066/itos-20241231.htm#2034780 Filing: 000095017025033066 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	−USD 134.4 million Exact value Exact value: -134400000 USD 2024-01-01 – 2024-12-31: -134400000 USD Inspect Net Income Open source Share or cite Citation for Net Income · iTeos Therapeutics, Inc. · 2024-12-31 iTeos Therapeutics, Inc. (edgar:1808865) Net Income: -134400000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T11:14:41Z Snapshot: 3bc84d46dc924d83216b56ecc732a1ddeff5737085046a07b53297302179d7bf Dimensions: Consolidated View: https://fundies.io/companies/edgar/1808865/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -134400000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1808865/000095017025033066/itos-20241231.htm#2129881 Filing: 000095017025033066 The citation records this snapshot. The page link may show a newer release later.	−USD 98.18 million Exact value Exact value: -98181000 USD 2024-01-01 – 2024-12-31: -98181000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · iTeos Therapeutics, Inc. · 2024-12-31 iTeos Therapeutics, Inc. (edgar:1808865) Operating Cash Flow: -98181000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T11:14:41Z Snapshot: 3bc84d46dc924d83216b56ecc732a1ddeff5737085046a07b53297302179d7bf Dimensions: Consolidated View: https://fundies.io/companies/edgar/1808865/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -98181000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1808865/000095017025033066/itos-20241231.htm#2019194 Filing: 000095017025033066 The citation records this snapshot. The page link may show a newer release later.	USD 1.63 million Exact value Exact value: 1633000 USD 2024-01-01 – 2024-12-31: 1633000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · iTeos Therapeutics, Inc. · 2024-12-31 iTeos Therapeutics, Inc. (edgar:1808865) Capital Expenditure: 1633000 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T11:14:41Z Snapshot: 3bc84d46dc924d83216b56ecc732a1ddeff5737085046a07b53297302179d7bf Dimensions: Consolidated View: https://fundies.io/companies/edgar/1808865/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1633000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1808865/000095017025033066/itos-20241231.htm#2033069 Filing: 000095017025033066 The citation records this snapshot. The page link may show a newer release later.	−USD 99.81 million Calculation and evidence -98181000 − 1633000 USD Exact free cash flow: -99814000 USD 2024-01-01 – 2024-12-31: -98181000 USD · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 1633000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · iTeos Therapeutics, Inc. · 2024-12-31 iTeos Therapeutics, Inc. (edgar:1808865) Free cash flow: -99814000 USD Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T11:14:41Z Snapshot: 3bc84d46dc924d83216b56ecc732a1ddeff5737085046a07b53297302179d7bf Dimensions: Consolidated View: https://fundies.io/companies/edgar/1808865?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -98181000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1808865/000095017025033066/itos-20241231.htm#2019194 Filing: 000095017025033066 Input fundies:CapitalExpenditure: 1633000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1808865/000095017025033066/itos-20241231.htm#2033069 Filing: 000095017025033066 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

24 filings · 1,514 latest values · 1,514 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001808865, 1808865, ITOS, edgar:1808865

Also known as iTeos Therapeutics, Inc.

iTeos Therapeutics, Inc.

Latest quarter

Revenue

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Net income

Operating cash flow

Capital expenditure

Free cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2024 2024-01-01 – 2024-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation